At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 259 enrolled
Drug / intervention
Collagenase Clostridium Histolyticumbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
In Brief
A Phase 2 clinical trial evaluating Collagenase Clostridium Histolyticum for Edematous Fibrosclerotic Panniculopathy and Cellulite. Completed, enrolled 259 participants across 15 sites.
Detailed Summary
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEdematous Fibrosclerotic Panniculopathy, Cellulite
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedOct 2016
Primary CompletionJun 2018
TodayJul 2026
First PostedOct 21, 2016
Enrollment StartOct 5, 2016
Primary CompletionJun 14, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.7 years ago
Interventions
Collagenase Clostridium Histolyticumbiological